[CMG Policy Radar] Pharmaceutical Industry 15th Five-Year Plan

China Macro Group | policy · business · strategy 

What it is

Issued jointly by ten bodies (MIIT, NDRC, MNR, MARA, MOFCOM, NHC, MEM, NHSA, NATCM, NMPA), the sectoral plan outlines 2030 objectives: revenue of above-scale pharma enterprises of at least RMB 3.5 trillion, average R&D intensity of at least 10% among listed firms, and first-in-class drugs making up at least 25% of the global total. It also targets 50 companies with annual revenue above RMB 10 billion.

Why it matters

The industry shifts from generic drug scale expansion to original innovative-driven growth, clustering generic drugs, biosimilars and API production around leading enterprises. It defines differentiated positioning for six specialized national pharmaceutical regional clusters, pushes domestic substitution of high-end pharma equipment and industrial software, while opening fast-track import approval channels for urgent clinical drugs and encouraging full-chain foreign localization.

Implications

Medium-High. Foreign pharma and medtech firms get market access and localization openings but will face stronger domestic (and global) competitors and substitution pressure on equipment and materials.

 Author:

Max de Bruyn Gomez

Analyst at CMG